Dalotuzumab ELISA Kit

Dalotuzumab ELISA Kit: A Powerful Tool for Studying and Targeting the Insulin-Like Growth Factor 1 Receptor Dalotuzumab, also known as MK-0646, is a monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). This receptor plays a crucial role in cell growth, proliferation, and survival, making it an attractive therapeutic target for various diseases, including cancer and diabetes. The use of Dalotuzumab ELISA Kit has revolutionized the study of IGF-1R and its role in different physiological and pathological processes.

Structure of Dalotuzumab

Dalotuzumab is a humanized IgG1 monoclonal antibody, meaning it is derived from human antibodies and has been engineered to have a longer half-life in the body. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains contain four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL1 and CL2) and one variable domain (VL). The variable domains are responsible for binding to the IGF-1R, while the constant domains provide stability and effector functions.

Activity of Dalotuzumab

Dalotuzumab binds to the IGF-1R with high affinity and specificity, preventing the binding of its natural ligands, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). This binding leads to the inhibition of downstream signaling pathways, such as the PI3K/AKT and MAPK pathways, which are involved in cell proliferation, survival, and migration. By blocking these pathways, Dalotuzumab can inhibit the growth and survival of cancer cells that overexpress IGF-1R. It can also sensitize cancer cells to chemotherapy and radiation therapy, making it a promising candidate for combination therapy.

Application of Dalotuzumab ELISA Kit

The Dalotuzumab ELISA Kit is a powerful tool for studying the expression and activity of IGF-1R in various biological samples. This kit utilizes a sandwich ELISA method, where the target protein (IGF-1R) is captured by a specific antibody and then detected by another antibody conjugated to an enzyme. The resulting color change is measured and correlates with the amount of IGF-1R present in the sample. This allows researchers to quantify the levels of IGF-1R in different tissues, cell lines, or body fluids, providing valuable insights into its role in different diseases.

The Dalotuzumab ELISA Kit has been used in numerous studies to investigate the expression of IGF-1R in different cancer types, such as breast, lung, and pancreatic cancer. It has also been used to assess the response to Dalotuzumab treatment in clinical trials. Additionally, this kit has been utilized to study the role of IGF-1R in other diseases, such as diabetes and cardiovascular diseases. By accurately measuring IGF-1R levels, researchers can better understand the mechanisms of action of this receptor and develop more effective therapies targeting it.

Conclusion

The Dalotuzumab ELISA Kit is a valuable tool for studying and targeting the IGF-1R, a critical receptor involved in various physiological and pathological processes. Its high specificity, sensitivity, and reproducibility make it an essential tool for researchers in the fields of cancer, diabetes, and other diseases. With the increasing interest in targeting IGF-1R for therapeutic purposes, the use of this kit is expected to continue to grow, providing valuable insights into the role of IGF-1R in health and disease.